A Randomized, Double-Masked, Vehicle-Controlled Proof-Of-Concept Study for Topically Delivered LHA510 as a Maintenance Therapy in Patients With Wet Age-Related Macular Degeneration (AMD)

Trial Profile

A Randomized, Double-Masked, Vehicle-Controlled Proof-Of-Concept Study for Topically Delivered LHA510 as a Maintenance Therapy in Patients With Wet Age-Related Macular Degeneration (AMD)

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs LHA 510 (Primary) ; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 24 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 15 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.
    • 15 Aug 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top